Sanofi successfully challenges rare disease patent in Europe
French biopharma giant overturns German rival’s patent at the European Patent Office | Revocation based on insufficient disclosure of antibody production | Appeal focused on detection method claims and biomarker specificity.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
20 May 2025 Boards of Appeal revokes Genzyme patent, handing win to Accord Healthcare | Teva and Hetero Labs also previously filed oppositions | Patent refers to Cerdelga, part of Sanofi’s Gaucher disease franchise.
20 May 2025 Boards of Appeal revokes Genzyme patent, handing win to Accord Healthcare | Teva and Hetero Labs also previously filed oppositions | Patent refers to Cerdelga, part of Sanofi’s Gaucher disease franchise.
20 May 2025 Boards of Appeal revokes Genzyme patent, handing win to Accord Healthcare | Teva and Hetero Labs also previously filed oppositions | Patent refers to Cerdelga, part of Sanofi’s Gaucher disease franchise.